TABLE 2.
Sample characteristics in the combined data set with network efficiency.
| NC (n = 25) | SCD (n = 17) | MCI (n = 8) | AD (n = 5) | Overall (n = 55) | Statistics (p) | |
|---|---|---|---|---|---|---|
| Sex (M/F) | 8/17 | 5/12 | 3/5 | 1/4 | 17/38 | 0.473 (.976) |
| Age | 65.7 ± 4.98 | 61.4 ± 8.03 | 69.5 ± 9.55 | 69.2 ± 8.91 | 65.2 ± 7.53 | 2.228 (.071) |
| Education | 12.6 ± 3.21 | 13.5 ± 3.94 | 13.1 ± 3.52 | 13.0 ± 4.24 | 13.0 ± 3.50 | 0.162 (.957) |
| APOEε4 carriers (percentage) | 28.0% | 35.3% | 75.0% | 40.0% | 38.2% | 5.76 (.218) |
| MMSE | 28.8 ± 1.48 | 29.0 ± 1.17 | 24.8 ± 3.11 | 12.0 ± 7.91 | 26.7 ± 5.61 | 16.406 (<.0001) |
| MoCA‐B | 24.9 ± 3.88 | 26.5 ± 2.45 | 19.4 ± 2.83 | 8.80 ± 5.76 | 23.1 ± 6.17 | 13.688 (<.0001) |
| Plasma Aβ42 (pg/mL) | 6.09 ± 1.21 | 5.71 ± 1.85 | 5.98 ± 1.27 | 4.84 ± 1.48 | 5.84 ± 1.47 | 0.808 (.523) |
| Plasma Aβ40 (pg/mL) | 100 ± 20.2 | 93.5 ± 28.3 | 111 ± 15.5 | 96.9 ± 37.3 | 99.4 ± 24.2 | 0.754 (.558) |
| Plasma Aβ42/Aβ40 | 0.0631 ± 0.0155 | 0.0625 ± 0.0115 | 0.0540 ± 0.0102 | 0.0517 ± 0.00658 | 0.0605 ± 0.0135 | 1.358 (.253) |
| Plasma NfL (pg/mL) | 15.1 ± 6.05 | 13.1 ± 4.82 | 18.8 ± 8.88 | 30.8 ± 7.68 | 16.4 ± 7.89 | 6.429 (<.001) |
| Plasma GFAP (pg/mL) | 114 ± 47.6 | 113 ± 49.9 | 201 ± 105 | 359 ± 69.9 | 149 ± 94.7 | 11.43 (<.0001) |
| Plasma p‐tau181 (pg/mL) | 1.53 ± 0.526 | 1.88 ± 0.729 | 3.07 ± 1.32 | 4.66 ± 2.28 | 2.14 ± 1.34 | 8.887 (<.0001) |
| Global efficiency | 6.55 ± 5.71 | 5.18 ± 2.94 | 5.05 ± 3.49 | 5.87 ± 6.30 | 5.85 ± 4.69 | 0.278 (.891) |
| Local efficiency | 13.2 ± 13.4 | 10.5 ± 6.23 | 10.5 ± 7.73 | 12.3 ± 11.1 | 11.9 ± 10.5 | 0.21 (.932) |
| Generalized local efficiency | 0.242 ± 0.0175 | 0.249 ± 0.0112 | 0.245 ± 0.0211 | 0.213 ± 0.0167 | 0.242 ± 0.0186 | 4.182 (<.01) |
Note: Continuous data are presented as the mean ± SD. Analyses of variance were utilized for continuous variables, while chi‐square tests were employed for categorical variables across NC, SCD, MCI, and AD.
Abbreviations: Aβ, amyloid β; AD, Alzheimer's disease; APOE, apolipoprotein E; GFAP, glial fibrillary acidic protein; MCI, mild cognitive impairment; MMSE, Mini‐Mental State Examination; MoCA‐B, Montreal Cognitive Assessment Basic; NC, normal control; NfL, neurofilament light chain; p‐tau, phosphorylated tau; SCD, subjective cognitive decline.